除了小分子抑制剂，核酸技术也开始在ACH治疗中得到应用。Ribomic开发的RBM-007，通过限制FGF2和FGFR3激活变体之间的过度相互作用发挥功能。2期临床结果显示，RBM-007的疗效与Vosoritide相近（1.5厘米/年），甚至有一名受试者年增长5厘米，且该试验中包括2周一次的注射频率，是当前在研药物中最长的给药间隔。
There was a 5% rise year-on-year on the number of people born in the UK sleeping rough.
。im钱包官方下载对此有专业解读
Complete digital access to quality FT journalism with expert analysis from industry leaders. Pay a year upfront and save 20%.
Chris Fayers, head of environment at Hinkley Point C, said the testing had gone "really well"
Credit: Liam Daniel / Netflix